主要参考文献
[1]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）黑色素瘤诊疗指南2019.北京：人民卫生出版社，2019.
[2]Coit DG，Thompson JA，Albertini MR，et al.Cutaneous melanoma，version 2.2019，NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw，2019，17（4）：367-402.
[3]NZGG.Clinical practice guidelines for the managementof melanoma in Australia and New Zealand.New Zealand Guidelines Group（NZGG），2018.
[4]Elmore JG，Elder DE，Barnhill RL，et al.Concordance and reproducibility of melanoma staging according to the 7th vs 8th edition of the AJCC cancer staging manual.JAMA Netw Open，2018，1（1）.
[5]李忠武，路爱萍，孔蕴薏，等.中国黑色素瘤规范化病理诊断专家共识（2017年版）.中华病理学杂志，2018，47（1）：7.
[6]Kimbrough CW，Mc Masters KM，Davis EG.Principles of surgical treatment of malignant melanoma.Surg Clin North Am，2014，94（5）：973-988.
[7]Park KG，Blessing K，Kernohan NM.Surgical aspects of subungual malignant melanomas.The Scottish Melanoma Group.Ann Surg，1992，216（6）：692-695.
[8]Stigall LE，Brodland DG，Zitelli JA.The use of Mohs micrographic surgery（MMS）for melanoma in situ（MIS）of the trunk and proximal extremities.J Am Acad Dermatol，2016，75（5）：1015-1021.
[9]Brandao PHDM，Bertolli E，Doria-Filho E，et al.In transit sentinel node drainage as a prognostic factor for patients with cutaneous melanoma.JSurg Oncol，2018，117（5）：864-867.
[10]Morton DL，Hoon DS，Cochran AJ，et al.Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma：therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.Ann Surg，2003，238（4）：538-549.
[11]Lens MB，Dawes M，Newton-Bishop JA，et al.Tumour thickness as a predictor of occult lymph node metastases in patients with stageⅠandⅡmelanoma undergoing sentinel lymph node biopsy.Br J Surg，2002，89（10）：1223-1227.
[12]Ling J，Tauscher R，Mehta V，et al.The Role for Sentinel Lymph Node Biopsy in the Management of Conjunctival Melanoma.Int Ophthalmol Clin，2017，57（1）：87-101.
[13]Mocellin S，Hoon DS，Pilati P，et al.Sentinel lymph node molecular ultrastaging in patients with melanoma：a systematic review and meta-analysis of prognosis.J Clin Oncol，2007，25（12）：1588-1595.
[14]Morton DL，Thompson JF，Cochran AJ，et al.Final trial report of sentinel-node biopsy versus nodal observation in melanoma.N Engl J Med，2014，370（7）：599-609.
[15]Testori A，Mozzillo N.Surgical techniques of melanoma and sentinel node biopsy.Semin Oncol，2002，29（4）：328-335.
[16]Scoggins CR，Martin RC，Ross MI，et al.Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.Ann Surg Oncol，2010，17（3）：709-717.
[17]Lens MB，Dawes M，Goodacre T，et al.Elective lymph node dissection in patients with melanoma：systematic review and metaanalysis of randomized controlled trials.Arch Surg，2002，137（4）：458-461.
[18]Verver D，Madu MF，Oude Ophuis CMC，et al.Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin.Br J Surg，2018，105（1）：96-105.
[19]Gonzalez，A.Sentinel lymph node biopsy：Past and present implications for the management of cutaneous melanoma with nodal metastasis.Am J Clin Dermatol，2018，19（Suppl 1）：24-30.
[20]Bigby M，Zagarella S，Sladden M，et al.Time to reconsider the role of sentinel lymph node biopsy in melanoma.J Am Acad Dermatol，2019，80（4）：1168-1171.(https://www.daowen.com)
[21]Faries MB，Thompson JF，Cochran AJ，et al.Completion dissection or observation for sentinel-node metastasis in melanoma.N Engl J Med.2017，376（23）：2211-2222.
[22]徐宇，朱蕙燕，陈勇，等.前哨淋巴结活检在中国皮肤和肢端恶性黑色素瘤患者诊治中的临床意义.中国癌症杂志，2018，28（11）：8.
[23]Chi Z，Li S，Sheng X，et al.Clinical presentation，histology，and prognoses of malignant melanoma in ethnic Chinese：A study of 522 consecutive cases.BMC Cancer，2011，11：85.
[24]van der Ploeg AP，van Akkooi AC，Rutkowski P，et al.Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.J Clin Oncol，2011，29（16）：2206-2214.
[25]Verver D，van Klaveren D，van Akkooi ACJ，et al.Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations.Eur J Cancer，2018，96：25-33.
[26]Yao KA，Hsueh EC，Essner R，et al.Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma？Ann Surg，2003，238（5）：743-747.
[27]Cornett WR，McCall LM，Petersen RP，et al.Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor：American college of surgeons oncology group trial Z0020.J Clin Oncol，2006，24（25）：4196-4201.
[28]Vyas A，Avritscher R，Ensor J，et al.Isolated limb infusion with cytotoxic agents：a simplified approach for venous access.Cancer，2010，116（2）：459-464.
[29]Andtbacka RH，Kaufman HL，Collichio F，et al.Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.J Clin Oncol，2015，33（25）：2780-2788.
[30]Hayes AJ，Clark MA，Harries M，et al.Management of in-transit metastases from cutaneous malignant melanoma.Br J Surg，2004，91（6）：673-682.
[31]Sosman JA，Moon J，Tuthill RJ，et al.A phase 2 trial of complete resection for stageⅣmelanoma：Results of southwest oncology group clinical trial S9430.Cancer，2011，117（20）：4740-4706.
[32]Howard JH，Thompson JF，Mozzillo N，et al.Metastasectomy for distant metastatic melanoma：Analysis of data from the first I）.Ann Surg Oncol，2012，19（8）：2547-multicenter selective lymphadenectomy trial（MSLT-2555.
[33]Faries MB，Mozzillo N，Kashani-Sabet M et al.Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases.Ann Surg Oncol，2017，24（13）：3991-4000.
[34]Robert C，Grob JJ，Stroyakovskiy D，et al.Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma.N Engl J Med，2019，[Epub ahead of print].
[35]Hodi FS，Chiarion-Sileni V，Gonzalez R，et al.Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma（Check Mate 067）：4-year outcomes of a multicentre，randomised，phase 3 trial.Lancet Oncol，2018，19（11）：1480-1492.
[36]Petrella TM，Robert C，Richtig E，et al.Patient-reported outcomes in KEYNOTE-006，a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.Eur J Cancer，2017，86：115-124.
[37]Blank CU，Rozeman EA，Fanchi LF，et al.Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stageⅢmelanoma.Nat Med，2018，24（11）：1655-1661.
[38]Blank CU，Rozeman EA，Fanchi LF，et al.A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.Nat Med，2019，25（3）：454-461.
[39]Amaria RN，Prieto PA，Tetzlaff MT，et al.Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of carein patients with high-risk，surgically resectable melanoma：a single-centre，open-label，randomised，phase 2 trial.Lancet Oncol，2018，19（2）：181-193.
[40]Amaria RN，Reddy SM，Tawbi HA，et al.Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.Nat Med，2018，24（11）：1649-1654.